{"success":true,"data":{"pressRelease":{"id":"31346","rtpr_id":"nGNX8BkJvf","ticker":"6855","exchange":"HKEX","all_tickers":["6855"],"title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-05-12T12:00:01.716Z","article_body":"ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage\nPharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma”\nor the “Company”), a global, commercial stage, integrated\nbiopharmaceutical company engaged in the discovery, development and\ncommercialization of novel, differentiated therapies to address unmet medical\nneeds in cancer, announced today that the Company’s management is scheduled\nto participate in three upcoming investor conferences.\n* B. Riley Commercial/Late-Stage Oncology Best Ideas Summit: One-on-one\nmeetings on May 18(th)\n* Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and\nfireside chat at 10:30 am EDT on May 19(th)\n* Jefferies Global Healthcare Conference in New York: One-on-one meetings and\npresentation at 8:10 am EDT on June 3(rd)\nThe webcasts for the fireside chat and presentation can be accessed by\nvisiting the Events\n(https://www.globenewswire.com/Tracker?data=xXW6RVIXBNVKxvZx88D3C_3ip252OJi7Q7x2_3iLQV5_0SAxirCPAbPhn3qlM-IZSrFwze_0DCsLlExef2brqH18hrc9G_LWtBPbxbxsuAo=)\npage in the Investor Relations section of Ascentage Pharma’s website.\n\nAbout Ascentage Pharma Group International\n\nAscentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage\nPharma” or the “Company”) is a global, commercial stage, integrated\nbiopharmaceutical company engaged in the discovery, development and\ncommercialization of novel, differentiated therapies to address unmet medical\nneeds in cancer. The Company has built a rich pipeline of innovative drug\nproducts and candidates that include inhibitors targeting key proteins in the\napoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase\ninhibitors, and protein degraders.\n\nThe Company’s first approved product, Olverembatinib, is the first novel\nthird-generation BCR-ABL1 inhibitor approved in China for the treatment of\npatients with CML in chronic phase (CML-CP) with T315I mutations, CML in\naccelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant\nor intolerant to first- and second-generation TKIs. It is covered by the China\nNational Reimbursement Drug List (NRDL). Ascentage Pharma is currently\nconducting an FDA-cleared global registrational Phase III trial, called\nPOLARIS-2, of Olverembatinib for CML, as well as global registrational Phase\nIII trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and\nSDH-deficient GIST patients, called POLARIS-3.\n\nThe Company’s second approved product, Lisaftoclax, is a novel Bcl-2\ninhibitor for the treatment of various hematologic malignancies. Lisaftoclax\nhas been approved by China’s National Medical Products\nAdministration (NMPA) for the treatment of adult patients with chronic\nlymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously\nreceived at least one systemic therapy including Bruton’s tyrosine kinase\n(BTK) inhibitors. The Company is currently conducting four global\nregistrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in\ncombination with BTK inhibitors in patients with CLL/SLL previously treated\nwith BTK inhibitors for more than 12 months with suboptimal response; the\nGLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in\nnewly diagnosed, elderly and unfit patients with AML; and the FDA-cleared\nGLORA-4 study in patients with newly diagnosed higher risk MDS.\n\nLeveraging its robust R&D capabilities, Ascentage Pharma has built a\nportfolio of global intellectual property rights and entered into global\npartnerships and other relationships with numerous leading biotechnology and\npharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and\nInnovent, in addition to research and development relationships with leading\nresearch institutions, such as Dana-Farber Cancer Institute, Mayo\nClinic, National Cancer Institute and the University of Michigan. For more\ninformation, visit https://ascentage.com/\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange\nAct of 1934, as amended. All statements, other than statements of historical\nfacts, contained in this press release may be forward-looking statements,\nincluding statements that express Ascentage Pharma’s opinions, expectations,\nbeliefs, plans, objectives, assumptions, or projections regarding future\nevents or future results of operations or financial condition. These\nforward-looking statements are subject to a number of risks and uncertainties\nas discussed in Ascentage Pharma’s filings with the SEC, including those set\nforth in the sections titled “Risk factors” and “Cautionary note\nregarding forward-looking statements” in its Annual Report on Form 20-F for\nthe year ended December 31, 2025, filed with the SEC on April 29, 2026, the\nsections headed “Forward-looking Statements” and “Risks Factors” in\nthe prospectus of the Company for its Hong Kong initial public offering dated\nOctober 16, 2019, and other filings with the SEC and/or The Stock Exchange of\nHong Kong Limited, where the Company’s ordinary shares are listed, it has\nmade or it makes from time to time that may cause actual results, levels of\nactivity, performance or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. The\nforward-looking statements contained in this presentation do not constitute\nprofit forecast by the Company’s management.\n\nAs a result of these factors, you should not rely on these forward-looking\nstatements as predictions of future events. The forward-looking statements\ncontained in this press release are based on Ascentage Pharma’s current\nexpectations and beliefs concerning future developments and their potential\neffects and speak only as of the date of such statements. Ascentage\nPharma does not undertake any obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nContacts\nInvestor Relations:\nStella Yang\nAscentage Pharma\nStella.Yang@ascentage.com\n+1 (301) 792-6286\n\nStephanie Carrington\nICR Healthcare\nAscentageIR@icrhealthcare.com\n+1 (646) 277-1282\n\nMedia Relations:\nSean Leous\nICR Healthcare\nAscentagePR@icrhealthcare.com\n+1 (646) 866-4012\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b9623a51-a13b-4b80-8152-61d5014f4a0a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8BkJvf","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","author":"Globe Newswire","ticker":"6855","created":"2026-05-12T12:00:01.716Z","tickers":["6855"],"exchange":"HKEX","article_body":"ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage\nPharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma”\nor the “Company”), a global, commercial stage, integrated\nbiopharmaceutical company engaged in the discovery, development and\ncommercialization of novel, differentiated therapies to address unmet medical\nneeds in cancer, announced today that the Company’s management is scheduled\nto participate in three upcoming investor conferences.\n* B. Riley Commercial/Late-Stage Oncology Best Ideas Summit: One-on-one\nmeetings on May 18(th)\n* Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and\nfireside chat at 10:30 am EDT on May 19(th)\n* Jefferies Global Healthcare Conference in New York: One-on-one meetings and\npresentation at 8:10 am EDT on June 3(rd)\nThe webcasts for the fireside chat and presentation can be accessed by\nvisiting the Events\n(https://www.globenewswire.com/Tracker?data=xXW6RVIXBNVKxvZx88D3C_3ip252OJi7Q7x2_3iLQV5_0SAxirCPAbPhn3qlM-IZSrFwze_0DCsLlExef2brqH18hrc9G_LWtBPbxbxsuAo=)\npage in the Investor Relations section of Ascentage Pharma’s website.\n\nAbout Ascentage Pharma Group International\n\nAscentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage\nPharma” or the “Company”) is a global, commercial stage, integrated\nbiopharmaceutical company engaged in the discovery, development and\ncommercialization of novel, differentiated therapies to address unmet medical\nneeds in cancer. The Company has built a rich pipeline of innovative drug\nproducts and candidates that include inhibitors targeting key proteins in the\napoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase\ninhibitors, and protein degraders.\n\nThe Company’s first approved product, Olverembatinib, is the first novel\nthird-generation BCR-ABL1 inhibitor approved in China for the treatment of\npatients with CML in chronic phase (CML-CP) with T315I mutations, CML in\naccelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant\nor intolerant to first- and second-generation TKIs. It is covered by the China\nNational Reimbursement Drug List (NRDL). Ascentage Pharma is currently\nconducting an FDA-cleared global registrational Phase III trial, called\nPOLARIS-2, of Olverembatinib for CML, as well as global registrational Phase\nIII trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and\nSDH-deficient GIST patients, called POLARIS-3.\n\nThe Company’s second approved product, Lisaftoclax, is a novel Bcl-2\ninhibitor for the treatment of various hematologic malignancies. Lisaftoclax\nhas been approved by China’s National Medical Products\nAdministration (NMPA) for the treatment of adult patients with chronic\nlymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously\nreceived at least one systemic therapy including Bruton’s tyrosine kinase\n(BTK) inhibitors. The Company is currently conducting four global\nregistrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in\ncombination with BTK inhibitors in patients with CLL/SLL previously treated\nwith BTK inhibitors for more than 12 months with suboptimal response; the\nGLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in\nnewly diagnosed, elderly and unfit patients with AML; and the FDA-cleared\nGLORA-4 study in patients with newly diagnosed higher risk MDS.\n\nLeveraging its robust R&D capabilities, Ascentage Pharma has built a\nportfolio of global intellectual property rights and entered into global\npartnerships and other relationships with numerous leading biotechnology and\npharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and\nInnovent, in addition to research and development relationships with leading\nresearch institutions, such as Dana-Farber Cancer Institute, Mayo\nClinic, National Cancer Institute and the University of Michigan. For more\ninformation, visit https://ascentage.com/\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995 and Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange\nAct of 1934, as amended. All statements, other than statements of historical\nfacts, contained in this press release may be forward-looking statements,\nincluding statements that express Ascentage Pharma’s opinions, expectations,\nbeliefs, plans, objectives, assumptions, or projections regarding future\nevents or future results of operations or financial condition. These\nforward-looking statements are subject to a number of risks and uncertainties\nas discussed in Ascentage Pharma’s filings with the SEC, including those set\nforth in the sections titled “Risk factors” and “Cautionary note\nregarding forward-looking statements” in its Annual Report on Form 20-F for\nthe year ended December 31, 2025, filed with the SEC on April 29, 2026, the\nsections headed “Forward-looking Statements” and “Risks Factors” in\nthe prospectus of the Company for its Hong Kong initial public offering dated\nOctober 16, 2019, and other filings with the SEC and/or The Stock Exchange of\nHong Kong Limited, where the Company’s ordinary shares are listed, it has\nmade or it makes from time to time that may cause actual results, levels of\nactivity, performance or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. The\nforward-looking statements contained in this presentation do not constitute\nprofit forecast by the Company’s management.\n\nAs a result of these factors, you should not rely on these forward-looking\nstatements as predictions of future events. The forward-looking statements\ncontained in this press release are based on Ascentage Pharma’s current\nexpectations and beliefs concerning future developments and their potential\neffects and speak only as of the date of such statements. Ascentage\nPharma does not undertake any obligation to update or revise any\nforward-looking statements, whether as a result of new information, future\nevents or otherwise.\n\nContacts\nInvestor Relations:\nStella Yang\nAscentage Pharma\nStella.Yang@ascentage.com\n+1 (301) 792-6286\n\nStephanie Carrington\nICR Healthcare\nAscentageIR@icrhealthcare.com\n+1 (646) 277-1282\n\nMedia Relations:\nSean Leous\nICR Healthcare\nAscentagePR@icrhealthcare.com\n+1 (646) 866-4012\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b9623a51-a13b-4b80-8152-61d5014f4a0a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-12T12:00:02.129380221Z","server_sent_at_ms":1778587202129},"received_at":"2026-05-12T12:00:02.332Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}